Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Stephen J. Luen"'
Autor:
Genevieve Dall, Karen Harris, Nonie Chan, Stephen J. Luen, Sophia Frentzas, Daphne Day, Michelle Barrett, Anna Kilgour, Mark Buzza
Publikováno v:
Current Oncology, Vol 31, Iss 8, Pp 4519-4530 (2024)
The Victorian Precision Oncology Summit, convened in 2023, was a joint initiative between the Victorian Comprehensive Cancer Centre Alliance (VCCC Alliance) and the Monash Partners Comprehensive Cancer Consortium (MPCCC) and was proposed to guide a c
Externí odkaz:
https://doaj.org/article/925a83d307a64d109d6bb755f122a7ca
Autor:
Agostina Stradella, Melissa Johnson, Sanjay Goel, Haeseong Park, Nehal Lakhani, Hendrik‐Tobias Arkenau, Matthew D. Galsky, Emiliano Calvo, Vicente Baz, Victor Moreno, Omar Saavedra, Stephen J. Luen, Song Mu, Qiting Wan, Victoria Chang, Wa Zhang, Minal Barve
Publikováno v:
Cancer Medicine, Vol 13, Iss 13, Pp n/a-n/a (2024)
Abstract Background Pamiparib is a potent, selective, poly (ADP‐ribose) polymerase 1/2 inhibitor that demonstrates synthetic lethality in cells with breast cancer susceptibility gene mutations or other homologous recombination deficiency. This two
Externí odkaz:
https://doaj.org/article/cc5999ad6e9e49dc84848eaa5c506e2e
Autor:
Zhi Ling Teo, Mark J. O’Connor, Stephanie Versaci, Kylie A. Clarke, Emmaline R. Brown, Luke W. Percy, Keilly Kuykhoven, Christopher P. Mintoff, Peter Savas, Balaji Virassamy, Stephen J. Luen, Ann Byrne, Sneha Sant, Geoffrey J. Lindeman, Phillip K. Darcy, Sherene Loi
Publikováno v:
npj Breast Cancer, Vol 9, Iss 1, Pp 1-16 (2023)
Abstract Novel therapeutic strategies that can effectively combine with immunotherapies are needed in the treatment of triple-negative breast cancer (TNBC). We demonstrate that combined PARP and WEE1 inhibition are synergistic in controlling tumour g
Externí odkaz:
https://doaj.org/article/bce6df774b064a2787512a67c74201f2
Autor:
Eden C. Andrew, Jeremy Lewin, Jayesh Desai, Lisa Orme, Anne Hamilton, Susie Bae, Wenying Zhu, Shannon Nicolson, Leila N. Varghese, Camilla B. Mitchell, Joseph H. A. Vissers, Huiling Xu, Sean M. Grimmond, Stephen B. Fox, Stephen J. Luen
Publikováno v:
Journal of Personalized Medicine, Vol 14, Iss 2, p 128 (2024)
Sarcomas are a heterogenous group of tumours that commonly carry poor prognosis with limited therapeutic options. Adolescents and young adults (AYAs) with sarcoma are a unique and understudied patient population that have only achieved modest surviva
Externí odkaz:
https://doaj.org/article/68d59d91727a47269eb52c73e523201c
Autor:
Sarah M. Trinder, Campbell McKay, Phoebe Power, Monique Topp, Bosco Chan, Santosh Valvi, Geoffrey McCowage, Dinisha Govender, Maria Kirby, David S. Ziegler, Neevika Manoharan, Tim Hassall, Stewart Kellie, John Heath, Frank Alvaro, Paul Wood, Stephen Laughton, Karen Tsui, Andrew Dodgshun, David D. Eisenstat, Raelene Endersby, Stephen J. Luen, Eng-Siew Koh, Hao-Wen Sim, Benjamin Kong, Nicholas G. Gottardo, James R. Whittle, Dong-Anh Khuong-Quang, Jordan R. Hansford
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
The mitogen-activated protein kinase (MAPK) pathway signaling pathway is one of the most commonly mutated pathways in human cancers. In particular, BRAF alterations result in constitutive activation of the rapidly accelerating fibrosarcoma–extracel
Externí odkaz:
https://doaj.org/article/b70dc0b5bc9c4f5f8e61a5acca858e20
Autor:
Courtney T. van Geelen, Peter Savas, Zhi Ling Teo, Stephen J. Luen, Chen-Fang Weng, Yi-An Ko, Keilly S. Kuykhoven, Franco Caramia, Roberto Salgado, Prudence A. Francis, Sarah-Jane Dawson, Stephen B. Fox, Andrew Fellowes, Sherene Loi
Publikováno v:
Breast Cancer Research, Vol 24, Iss 1, Pp 1-3 (2022)
Externí odkaz:
https://doaj.org/article/cb99f00f69a94e658b278335ef236f7b
Autor:
Courtney T. van Geelen, Peter Savas, Zhi Ling Teo, Stephen J. Luen, Chen-Fang Weng, Yi-An Ko, Keilly S. Kuykhoven, Franco Caramia, Roberto Salgado, Prudence A. Francis, Sarah-Jane Dawson, Stephen B. Fox, Andrew Fellowes, Sherene Loi
Publikováno v:
Breast Cancer Research, Vol 22, Iss 1, Pp 1-13 (2020)
Abstract Background Metastatic breast cancer remains incurable. Next-generation sequencing (NGS) offers the ability to identify actionable genomic alterations in tumours which may then be matched with targeted therapies, but the implementation and ut
Externí odkaz:
https://doaj.org/article/b141443b8fee419ca30bd111eea7af03
Autor:
Sathana Dushyanthen, Zhi Ling Teo, Franco Caramia, Peter Savas, Christopher P. Mintoff, Balaji Virassamy, Melissa A. Henderson, Stephen J. Luen, Mariam Mansour, Michael H. Kershaw, Joseph A. Trapani, Paul J. Neeson, Roberto Salgado, Grant A. McArthur, Justin M. Balko, Paul A. Beavis, Phillip K. Darcy, Sherene Loi
Publikováno v:
Nature Communications, Vol 8, Iss 1, Pp 1-18 (2017)
MEK inhibition in breast cancer is associated with increased tumour infiltrating lymphocytes (TILs), however, MAPK activity is required for T cells function. Here the authors show that TILs activity following MEK inhibition can be enhanced by agonist
Externí odkaz:
https://doaj.org/article/9dca7cf8454b4a3b9462fc4df89bf7de
Publikováno v:
Frontiers in Oncology, Vol 7 (2017)
The interest in tumor-infiltrating lymphocytes (TILs) as a prognostic biomarker in breast cancer has grown in recent years. Biomarkers must undergo comprehensive evaluation in terms of analytical validity, clinical validity and clinical utility befor
Externí odkaz:
https://doaj.org/article/ea2a5681d2d848fc9068b8180609ef00
Autor:
Ran Li, Sneha Sant, Emmaline Brown, Franco Caramia, Bronte Nikolic, Kylie Clarke, Ann Byrne, Luis E Lara Gonzalez, Peter Savas, Stephen J Luen, Zhi Ling Teo, Balaji Virassamy, Paul J Neeson, Phillip K Darcy, Sherene Loi
Publikováno v:
JNCI: Journal of the National Cancer Institute.
Background PD-1 and PD-L1 inhibitors have poor efficacy in patients with trastuzumab-resistant advanced HER2-positive breast cancer. Tucatinib is a potent, selective anti-HER2 tyrosine kinase inhibitor with proven clinical benefit in the advanced set